Wallace BK, Su ZT, Flynn JP, Garman TS, Weitzner A, Rezaee ME, et al. National trends in diagnoses of subtype histologies in bladder cancer: A population-based study based on the SEER database. Urol ...

Patients with bone-protecting agent use versus no bone-protecting agent had similar baseline characteristics: ...

Daniel George presents the CAPItello-281 study examining capivasertib combined with abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer. The study screened over 6,000 patients ...

As of September 2025, 15 patients have been recruited across 8 centers. Spain, Belgium, and Ireland, with 15 centers, will be open for inclusion in Q4 of 2025, with 9 more centers in France also being ...

We aimed to evaluate the outcomes of Thulium fiber laser enucleation of the prostate (ThuFLEP) in men with prostate volumes (PV) ≥ 150 mL and to compare them with those with PV < 150 mL. We ...

Scott Sellinger discusses federal government shutdown impacts on healthcare delivery with Phillip Koo, highlighting critical operational challenges facing independent urology practices. Medicare ...

Prostate cancer is driven by oncogenic transcription factor enhanceosomes comprising chromatin and epigenetic regulators. The lysine acetyltransferases p300 and CREB-binding protein (CBP) are key ...

The evaluation and classification of renal neoplasia has become increasingly complex and challenging. TFE3-rearranged renal cell carcinoma and TFEB-altered renal cell carcinoma are a rare subset of ...

At the 2025 UCSF-UCLA PSMA Conference, Thomas Hope challenges using PSMA PET/CT for restaging during radioligand therapy, advocating instead for post-treatment SPECT/CT imaging. While both modalities ...

At the 2025 UCSF-UCLA PSMA Conference, Tanya Dorff discusses PSMA-targeted immunotherapy approaches beyond radioligand therapy. She reviews Poseida's P-PSMA-101 CAR T experience, where promising ...

Focal therapy (FT) has quickly emerged over the last few decades as a prostate cancer (CaP) treatment option due to the growing research indicating more favorable side effects compared to radical ...

At the 2025 UCSF-UCLA PSMA Conference, Irène Buvat discusses how AI can simplify personalized dosimetry in radiopharmaceutical therapy, addressing the "catch-22" where complexity limits clinical use ...